Form 4: Quince Therapeutics CBO/COO Exercises Stock Options

Brendan Hannah, CBO, COO & CCO of Quince Therapeutics, Inc., increased his direct beneficial ownership by exercising employee stock options.

Summary

• Brendan Hannah, the Chief Business Officer, Chief Operating Officer, and Chief Commercial Officer of Quince Therapeutics, Inc. (QNCX), exercised employee stock options on December 5, 2025.
• He acquired 2,271 common shares at an exercise price of $0.55 per share.
• He also acquired an additional 25,280 common shares at an exercise price of $0.94 per share.
• Following these transactions, Mr. Hannah's direct beneficial ownership of common shares in Quince Therapeutics, Inc. increased to 361,827.
• The exercised options were part of two grants: 103,500 options granted on May 19, 2022, vesting over four years, and 225,000 options granted on February 2, 2023, vesting over four years.
• After the exercises, Mr. Hannah beneficially owns 45,168 remaining employee stock options from the May 2022 grant and 199,720 remaining employee stock options from the February 2023 grant.

Sentiment

Score: 7

Explanation: The exercise of employee stock options by a key executive indicates confidence in the company's future prospects and aligns management's interests with shareholders, which is generally a positive signal.

Positives

• The exercise of employee stock options by a key executive, Brendan Hannah, indicates management's confidence in the company's future prospects.
• The increase in direct beneficial ownership aligns the executive's financial interests more closely with those of shareholders.

Future Outlook

The filing details the vesting schedules for the employee stock options, indicating continued vesting over a four-year period for both grants, with full vesting on the fourth annual anniversary of their respective vesting commencement dates.

Industry Context

This insider transaction reflects an executive's decision to exercise previously granted stock options, which is a common form of executive compensation. It does not directly relate to broader industry trends but signals the executive's personal investment and confidence in the company within its sector.

Comparison to Industry Standards

• Not directly applicable as this filing reports an individual executive's stock option exercise, not company performance metrics that are typically benchmarked against industry peers.

Related Party Transactions

• The transactions involve the exercise of employee stock options previously granted by Quince Therapeutics, Inc. to its executive, Brendan Hannah, which are considered related party transactions as part of executive compensation.

Stakeholder Impact

• Shareholders may view the executive's increased direct ownership as a positive indicator of management's belief in the company's long-term value.
• Employees may see this as a sign of stability and confidence from leadership.

Next Steps

• Continued vesting of the remaining employee stock options according to their respective schedules.

Key Dates

Recommendation

While the insider's exercise of stock options is a positive signal, indicating management confidence, a single Form 4 filing typically does not provide sufficient information to warrant a 'buy' or 'sell' recommendation. It suggests a positive sentiment but requires further analysis of the company's fundamentals and market conditions.

Keywords

Quince Therapeutics, QNCX, Brendan Hannah, Stock Options, Insider Trading, Form 4, Beneficial Ownership, Executive Compensation